financetom
Business
financetom
/
Business
/
Gujarat Alkalies Q1FY22: Company has recovered almost to pre-COVID levels, says Executive Director
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gujarat Alkalies Q1FY22: Company has recovered almost to pre-COVID levels, says Executive Director
Aug 12, 2021 6:16 AM

Gujarat Alkalies posted good Q1 earnings clocking in an improvement both on a year-on-year and sequential basis. Revenue is up 50 percent and margin has expanded to nearly 18 percent.

G S Paliwal, Executive Director - Marketing of the company said, “It has been a very good quarter for the company this year and we have seen the performance in terms of volumes, we have been seeing the performance in terms of prices. So, definitely despite second wave we have performed much better way than what it has been during the COVID-19 previous year.”

“On account of the prices, prices have been continuously moving upside since last quarter of last financial year and that has supported well in this Q1 as well. “

On caustic soda Paliwal said, “Caustic soda has been hovering around $370-375 at this moment in the international market, and that is the impact which we can see in the domestic market as well. Last quarter it was somewhere close to around $220-225, so it is almost $100-125 up compared to the last previous year in this quarter.”

On capacity utilisation he said, “Last year if you really look at our revenue was close to Rs 453 crores and it has increased from Rs 453 crores to Rs 701 crores. In absolute numbers, if we really look at it is about 54-55 percent increase in revenue. On production front also, last year the capacity utilisation during the quarter was around 70-75 percent, it has raised to 95 percent plus, so both on volume front as well as on price front we have recovered almost to the pre-pandemic level.”

For full management commentary, watch the video.

(Edited by : Aditi Gautam)

First Published:Aug 12, 2021 3:16 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Apr 24, 2024
April 24 (Reuters) - Hasbro ( HAS ) reported a smaller-than-expected drop in first-quarter sales and handily beat profit estimates on Wednesday, as leaner inventories and steady digital gaming revenue helped cushion a drag from softer demand for toys. The Play-Doh maker has grappled with weakening demand over the past year amid a pullback in discretionary spending and tight inventory...
Veeva Systems Insider Sold Shares Worth $681,116, According to a Recent SEC Filing
Veeva Systems Insider Sold Shares Worth $681,116, According to a Recent SEC Filing
Apr 24, 2024
06:35 AM EDT, 04/24/2024 (MT Newswires) -- Alan Mateo, EVP Global Sales, on April 23, 2024, sold 3,391 shares in Veeva Systems ( VEEV ) for $681,116. Following the Form 4 filing with the SEC, Mateo has control over a total of 29,332 shares of the company, with 21,983 shares held directly and 7,349 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1393052/000162828024017492/xslF345X03/wk-form4_1713913758.xml...
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Apr 24, 2024
06:31 AM EDT, 04/24/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Wednesday that an open-label extension, or OLE, study to its late-stage NefIgArd study showed a treatment response that was consistent with the NefIgArd study's findings. The open-label extension study enrolled 119 patients, 45 of whom were involved in the previous late-stage study and met its endpoints even...
Entergy misses quarterly profit estimates on higher expenses
Entergy misses quarterly profit estimates on higher expenses
Apr 24, 2024
April 24 (Reuters) - Electric utility company Entergy Corp ( ETR ) missed Wall Street estimates for first-quarter profit on Wednesday, hurt by higher operating expenses and lower commercial sales. On an adjusted basis, the firm posted a profit of $1.08 per share for the quarter that ended March 31, below the average analysts' estimate of $1.51 per share, according...
Copyright 2023-2026 - www.financetom.com All Rights Reserved